BioPark Regensburg GmbH
The BioPark Regensburg GmbH is the management and administrative headquarters of the biotechnology research cluster known as BioRegio Regensburg in East Bavaria. Located strategically at the northernmost point of the Danube, in the Austrian-Czech-German triangle, the area is regarded as the gateway to the East of the extended European Union. Currently 50 firms with 3.872 employees are active in the field of life sciences in BioRegio Regensburg. As a result it has become the most important region for Biotechnology in Bavaria, second only to Munich.
Projects at the site and in the region
In 2014 the BioPark Regensburg celebrated its 15 year anniversary. In this period over 254 million € have been invested in the development of the "life sciences", of this solely 102 million € in venture capital. 37 companies have been founded since 1999 and the number of employees has increased more than six-fold to 2600. In 2006 the company Geneart AG was the first of all BioPark companies that went to the Frankfurt Stock Exchange and became part of the ThermoFischer cooperation 2010. Until 2016 AMGEN Research GmbH is the first research center in Europe that is from one of the largest Biotech companies in the USA. In Regensburg ten million compounds have been analyzed annually in order to identify new structures for the development of innovative medication. In 2008 BioPark Regensburg was awarded "Landmark" by the Federal Initiative "Germany – Land of Ideas". From 2007 until 2015 the BioPark has been part of spokesman circle for the Council of German Bioregions. Since 2011 BioPark takes an active part as board member and since 2014 as vice-president of the federal association of German innovation-, technology- and new business centres (BVIZ). Since 2013 Biopark additionally takes part in the speaker committee of the association of Bavarian technology- and new business centres (ARGE-TGZ).
A range of companies at BioRegio Regensburg have developed into international production locations for clean rooms. These include pharmaceutical companies such as Bionorica SE and Haupt Pharma Amareg GmbH, and also biotechnology companies such as Syntacoll GmbH, PAN Biotech GmbH and medical technology companies such as RKT Roding Kunststoff-Technik GmbH, Raumedic AG and Gerresheimer Regensburg GmbH.
Innovation and success require constant analysis and development, and this is also true for the BioPark in Regensburg. In regular location analyses, the potential for development of BioRegio Regensburg has been analyzed and founded the Agency IA-Biotech to realize this. BioRegio Regensburg in Eastern Bavaria and BioPark Regensburg on the university campus provide an extensive expertise in the fields of business set-up, acquisition of subsidies, financing, development and strategies of companies, internationalization, company take-over, licensing procedure and integration processes.
With the new network “BIOPARK8 Brain Network” BioPark combines that knowledge at one site, rendered it more visible and placed it at the disposal. Eight personalities with extensive enterprising expertise serve as coach and advisor, but also as participant in discussions and platform speaker around topics such as biotechnology, pharma, diagnostics, analytics, medical engineering and clean energy in Regensburg.
In the latest project BioPark coordinates the expansion of cluster actvities in the field of health management. An extensive production site analysis was followed by intensive workshops covering the topics of cellular therapy, oncology, digitalization, aging society, professionals and apprenticeship, as well as site marketing and economic promotion. The potential of this economic branch and the opportunities for the region should be captured in a masterplan. Regensburg currently booms as “city of health”. The whole sector provides labor for 15.500 people and generated a total sale of 1.4 billion in the location of Regensburg recently.